Tamoxifen (Nolvadex*) is widely used as a first line therapy in the management of breast cancer. Early clinical results indicated that the threshold of consistent therapeutic activity lay between 10 and 20mg daily. Ward (1973) , in a small randomised comparison of 10mg bd and 20mg bd, reported a greater tumour response rate at the higher dose, although the difference was not statistically significant. The only other direct comparison of two dosages was a non-randomised study (Lerner et al., 1976) in which the results were considered inconclusive. A review of 19 major clinical trials (Mouridsen et al., 1978) suggested that a dose of 40mg daily was associated with a higher overall response than 20mg daily (39% versus 28%) but this conclusion needs confirming in a prospective randomised trial.
Recently a method for analysing concentrations of tamoxifen in serum has become available (Adam et al., 1980a) . No correlation between serum concentrations and clinical response was found in 39 patients but it was recommended that a further study in a larger number of patients was required (Patterson et al., 1980) . Patients were allocated, double blind, to receive tamoxifen either 0mg or 20mg twice daily in the form of matching tablets by the hospital pharmacist using a computer-generated randomisation code. Because the supply of matching 20mg tablets was limited, only 4 months' treatment was provided for each patient. After 4 months' therapy the code for individual patients was broken and further tamoxifen was prescribed using conventional sales material ("Nolvadex" 10mg).
General clinical status, side effects and soft tissue disease were evaluated monthly for the first 4 months. Bone and lung lesions were assessed radiologically on entry and at 3 months. Hepatic involvement was judged clinically by measuring liver size below the costal margin. Tumour response to therapy was assessed according to the U.I.C.C. criteria (Hayward et al., , 1978 Tumour response data were audited by exchange of record forms between the principal investigators of the two centres.
The proportion of responders has been analysed using logistic regression. The terms fitted were dose, age, disease-free interval, presence/absence of primary tumour and dominant site. Duration of response has been compared between the two dose groups using the logrank test (Peto et al., 1977) .
Where possible two 10ml samples of blood were taken from each patient at least one month apart between the 8th and 16th week of treatment by which time steady state kinetics were assumed to have been reached (Patterson et al., 1980) . Serum was analysed for tamoxifen and desmethyl metabolite concentrations using the method described by Adam et al. (1980b Response with respect to age and disease free interval (DFI) are shown in Tables VI and VII. The differences in response rates between the various strata did not achieve statistical significance, although some trend towards an increasing response rate with age up to 80 years and length of DFI is evident. Table X shows the results of analysis of variance of serum concentrations allowing for dose and response (CR + PR) and the interaction between these parameters. There were no significant differences between responders and non-responders either within a dose group or on combining dose groups. The mean serum concentrations of 159ngml-' and 273ngml-1 for 10 and 20mgbd respectively were markedly different (P<0.0001). Figure 1 shows the scattergram of serum concentrations of tamoxifen in the two dose groups.
In the group in which steady state kinetics were proven, the mean ratio of metabolite to unchanged drug concentration was 1.79+0.01 (n=25) for the 10mgbd group and 1.87+0.08 (n=20) for the 20mgbd dose group. These were not significantly different. This suggests there was no difference in compliance between the two groups of patients. advantage for a tamoxifen dose of 20 mg bd compared with 10 mg bd. In a previous smaller comparison between 20 and 40mg daily (Ortiz de Taranco et al., 1979) , the objective response rates were also not significantly different. However, consideration of the NC group brought the total response rates (CR + PR + NC) to 51% for 20mg daily and 79% for 40mg daily thus demonstrating a statistically significant advantage for the higher dose. The corresponding overall response rates in our trial were 50% and 57% (Henningsen & Amerger, 1977; Cavalli et al., 1983) . Premenopausal patients were excluded from this trial. The efficacy of doses as low as 10mgbd in such patients has been questioned on the grounds that this dose may not completely antagonise their high endogenous levels of oestrogens (Manni & Pearson, 1980; Santen et al., 1981) . The results of this study should not therefore be extrapolated to the premenopausal age group. This study also does not exclude the possibility of a response to higher doses after failure at lower doses; 23% (7/30) of patients with documented progressive disease on 20mg tamoxifen daily have previously been reported to have achieved disease stabilisation for up to 15 months when the dose was increased to 40mg daily although no objective responses were observed (Stewart et al., 1982) . We have now described one complete remission in a patient given 20mg bd when previously unresponsive to 10mg bd. However, one patient with progressive disease developed a partial response with no change in therapy.
It is interesting that the overall response rate, side effect profile and prognostic trends emerging from the trial (i.e. correlation of response to dominant site, age, disease free interval etc.) are similar to those reported in reviews of published clinical trials (Mouridsen et al., 1978; Patterson, 1981) suggesting that our patient sample was representative of the population normally treated. The lower response rate in patients with primary tumours, irrespective of dose, is probably a function of the size of the lesion (5cm by definition of "inoperable"), making the criterion for partial response (more than 50% decrease in the product of perpendicular diameters) more difficult to achieve because of the increased tumour burden. This is supported by the fact that addition of the NC category obliterates the significant difference in response rates for patients with and without primary tumour (52% and 56% respectively).
Some patients clearly required longer than 4 months to achieve an optimal therapeutic response. Indeed, two patients who had actually been classified as having progressive disease at 4 months subsequently responded (one CR and one PR). This observation has previously been reported by Glick et al. (1980) who recommended that tamoxifen should not be discontinued unless progressive disease is documented or significant symptomatic deterioration occurs.
In both groups of patients the serum concentration of tamoxifen varied widely. This probably results from a combination of a population spread in half-life and presumed invariable, but unknown degrees of incomplete compliance. However, the spread was similar in both groups and the mean serum concentration in the 20mgbd group was approximately double that for the lower dose. Despite this difference in serum concentrations, there was no identifiable difference in clinical response. One possible explanation might be that the circulating tamoxifen levels may not necessarily reflect cytoplasmic concentrations in target cells, particularly in tumours with abnormal vasculature. Furthermore, oestrogen receptor status, which may be an important factor in determining response to endocrine therapy, was not measured in patients in this study and hence receptor imbalance between the patient groups cannot be excluded.
In conclusion, tamoxifen has been confirmed to be a safe and effective therapy for postmenopausal women with advanced breast cancer, the mean objective response rate being 32% with less than 1% of patients stopping treatment because of side effects. However, no statistically significant advantage for 40mg daily over 20mg daily has been found, neither was there any evidence of a correlation between tumour response and serum tamoxifen level.
